Immunovant's total assets for Q2 2025 were $515.71M, a decrease of -12.54% from the previous quarter. IMVT total liabilities were $66.65M for the fiscal quarter, a 48.06% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.